TFFP Stock Overview
About the company
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company’s lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.
Snowflake Analysis
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
TFF Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.75 |
| 52 Week High | US$7.70 |
| 52 Week Low | US$0.62 |
| Beta | 1.21 |
| 1 Month Change | 13.64% |
| 3 Month Change | -18.30% |
| 1 Year Change | -88.44% |
| 3 Year Change | -78.63% |
| 5 Year Change | n/a |
| Change since IPO | -85.21% |
Recent News & Updates
Recent updates
Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans?
Sep 27
TFF Pharma: The Potential Is Still Very Much Present
Aug 29TFF Pharmaceuticals: Q3 Data Is Pivotal In So Many Ways
Aug 09TFF Pharmaceuticals expands R&D operations with new Austin facility
Jul 14TFF Pharmaceuticals: A Highly Attractive Basket Of Options
May 23We Think TFF Pharmaceuticals (NASDAQ:TFFP) Needs To Drive Business Growth Carefully
May 17Here's Why We're Not Too Worried About TFF Pharmaceuticals' (NASDAQ:TFFP) Cash Burn Situation
Jan 06TFF Pharmaceuticals: Upside Catalysts Starting To Show Up Amid Omicron, But Timidly
Dec 02Companies Like TFF Pharmaceuticals (NASDAQ:TFFP) Are In A Position To Invest In Growth
Sep 16TFF Pharmaceuticals: Cautiously Optimistic
Sep 09TFF Pharma's Platform Is Highly Relevant In The Battle Against The Pandemic
Jul 27TFF Pharmaceuticals: Looking Attractive At These Prices
Jun 03Companies Like TFF Pharmaceuticals (NASDAQ:TFFP) Are In A Position To Invest In Growth
Mar 30How Much Of TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Do Insiders Own?
Feb 23TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Insiders Increased Their Holdings
Jan 19
Dosing underway TFF Pharma's mid-stage study with inhaled voriconazole
Dec 15Companies Like TFF Pharmaceuticals (NASDAQ:TFFP) Are In A Position To Invest In Growth
Dec 15TFF Pharma inks development pact with Augmenta for COVID-19 therapies
Nov 02Shareholder Returns
| TFFP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -7.4% | -1.3% | 0.8% |
| 1Y | -88.4% | -5.3% | -14.2% |
Return vs Industry: TFFP underperformed the US Pharmaceuticals industry which returned -5.3% over the past year.
Return vs Market: TFFP underperformed the US Market which returned -14.2% over the past year.
Price Volatility
| TFFP volatility | |
|---|---|
| TFFP Average Weekly Movement | 15.7% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TFFP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: TFFP's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
TFF Pharmaceuticals, Inc. Fundamentals Summary
| TFFP fundamental statistics | |
|---|---|
| Market Cap | US$27.14m |
| Earnings (TTM) | -US$34.45m |
| Revenue (TTM) | US$195.02k |
139.2x
P/S Ratio-0.8x
P/E RatioIs TFFP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TFFP income statement (TTM) | |
|---|---|
| Revenue | US$195.02k |
| Cost of Revenue | US$21.26m |
| Gross Profit | -US$21.06m |
| Other Expenses | US$13.38m |
| Earnings | -US$34.45m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.95 |
| Gross Margin | -10,801.04% |
| Net Profit Margin | -17,663.02% |
| Debt/Equity Ratio | 0% |
How did TFFP perform over the long term?
See historical performance and comparison